Press Releases

Press Releases
Date Title and Summary View
May 24, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced that the Company's Board of Directors authorized the repurchase of an additional $3 billion of the Company's common stock. In addition, the Company plans to enter into an accelerated share repurchase (ASR) agreement to repurchase a...
May 22, 2018 Presentations highlight Celgene's ongoing innovative research, including the use of CAR T cell therapies to treat multiple myeloma and lymphoma, and therapies for the treatment of multiple blood disorders, including multiple myeloma, lymphoma, leukemia, myelodysplastic syndromes and beta-thalassemia ...
May 16, 2018 Presentations highlight the value of innovative research in key disease areas including multiple myeloma, lymphoma, acute myeloid leukemia and squamous non-small cell lung cancer, as well as novel CAR T technology SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) to...
May 14, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) plans to present at four upcoming investor conferences and events where Celgene management will provide an overview of the Company. The events will be webcast live and will be available in the Investor Relations section of the Company's website at...
May 4, 2018 — Q1:18 total net product sales of $3,531 million, increased 20% Y/Y — Raising full-year 2018 revenue guidance to high end of previous range — Completion of Juno Therapeutics & Impact Biomedicines acquisitions will strengthen pipeline and capabilities ...
Apr 30, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) today announced the appointment of Jennifer Dudinak, Pharm.D., as Senior Vice President, Global Regulatory Affairs, reporting to Jay Backstrom, M.D., Chief Medical Officer, effective April 30, 2018. Jennifer will be responsible for regulatory ...
Apr 24, 2018 Reductions in annualized relapse rates shown in pivotal trials with ozanimod were consistent in subgroups including baseline disability, gadolinium-enhanced lesion status and prior exposure to disease-modifying therapies versus interferon beta-1a (Avonex®) Ozanimod showed effects on cortical ...
Apr 19, 2018 Gilla Kaplan, Ph.D., retiring from Board of Directors after 20 years of service US health insurance expert Patricia Hemingway Hall elected to Board of Directors Juno Therapeutics co-founder and former CEO Hans Bishop elected to Board of Directors ...
Apr 17, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) plans to present at three upcoming investor conferences where Celgene management will provide an overview of the Company. The conferences will be webcast live and will be available in the Investor Relations section of the Company's website at www....
Apr 9, 2018 SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Friday, May 04, 2018 at 9 a.m. ET to discuss first quarter 2018 financial and operational results. The first quarter results will include the financial and operational results of Juno ...
1
... NextLast
Add to Briefcase = add release to Briefcase